Iclaprim: Phase II started

ARPN began a double-blind, U.S. Phase II trial in >130 patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) to compare 2 dos...